| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MUC6 |
| Uniprot No | Q6W4X9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MUC6重组蛋白的模拟参考文献示例(建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"Recombinant expression and functional characterization of human MUC6 mucin in gastric cancer models"*
**作者**: Wang, X. et al.
**摘要**: 研究报道了在哺乳动物细胞中重组表达MUC6蛋白的方法，并验证其在胃癌细胞系中通过调节EGFR信号通路抑制肿瘤侵袭的作用。
2. **文献名称**: *"Glycosylation analysis of recombinant MUC6 mucin produced in HEK293 cells"*
**作者**: Kim, S. & Park, J.H.
**摘要**: 利用HEK293细胞系统表达MUC6重组蛋白，通过质谱分析其糖基化模式，揭示了糖链结构对MUC6在黏膜屏障功能中的关键影响。
3. **文献名称**: *"MUC6 recombinant protein as a diagnostic marker for pancreatic cysts"*
**作者**: Thompson, L.A. et al.
**摘要**: 开发了基于重组MUC6蛋白的ELISA检测方法，证明其在区分胰腺囊性肿瘤良恶性中的潜在临床价值。
4. **文献名称**: *"In vitro binding of Helicobacter pylori to recombinant MUC6 peptides"*
**作者**: Costa, A.M. et al.
**摘要**: 通过重组MUC6蛋白片段实验，发现其特异性结合幽门螺杆菌表面蛋白，提示MUC6在胃部抗菌防御中的机制。
---
**备注**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索关键词(如“MUC6 recombinant protein”“recombinant MUC6 expression”)获取最新研究。
MUC6. a member of the mucin protein family, is a high-molecular-weight glycoprotein predominantly expressed in epithelial cells of mucosal tissues, particularly in the gastrointestinal tract, stomach, and salivary glands. Structurally, it features a central tandem repeat domain rich in serine, threonine, and proline residues, which serves as a scaffold for extensive O-glycosylation. This glycosylation confers hydrophilicity and viscoelasticity, enabling MUC6 to form protective gel-like barriers that lubricate epithelial surfaces, shield against pathogens, and regulate microbial interactions. Dysregulation of MUC6 has been linked to gastric diseases, inflammatory conditions, and cancers, where its aberrant expression may influence tumor progression or immune evasion.
Recombinant MUC6 protein is engineered using expression systems like mammalian cells (e.g., HEK293 or CHO) to preserve post-translational modifications, or prokaryotic systems (E. coli) for non-glycosylated forms. The production involves cloning the MUC6 gene (located on chromosome 11p15.5) into expression vectors, followed by purification via affinity chromatography. Researchers utilize recombinant MUC6 to study its role in mucosal homeostasis, host-pathogen interactions, and disease mechanisms. It also serves as an antigen for antibody development in diagnostic assays or as a therapeutic target. Challenges include maintaining glycosylation patterns in vitro and resolving structural complexity. Current studies focus on its potential as a biomarker for early cancer detection and its utility in developing mucin-based therapeutics.
×
